home / stock / bntx / bntx articles

BNTX Articles, BioNTech SE - From 01/17/24

Stock Information
Company Name: BioNTech SE
Stock Symbol: BNTX
Market: NYSE
Website: biontech.de
Menu
BNTX BNTX Quote BNTX Short BNTX News BNTX Articles BNTX Message Board
Get BNTX Alerts

News, Short Squeeze, Breakout and More Instantly...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against BioNTech SE (BNTX) | Benzinga

NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the...
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' | Benzinga

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. "I think that Stepha...

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE (BNTX) | Benzinga

SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and...

BIONTECH SE SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX) | Benzinga

NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of BioNTech SE (NASDAQ:BNTX)? Did you purcha...
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | Benzinga

NEW YORK, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, no...

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates | Benzinga

SHANGHAI, Jan. 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufa...

BioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025 | Benzinga

On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P. Morgan Healthcare Conference and said it expects to grow it...
P/E Ratio Insights for BioNTech | Benzinga

In the current market session, BioNTech Inc. (NASDAQ:BNTX) share price is at $109.31, after a 2.30% decrease. Over the past month, the stock spiked...

Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada | Benzinga

The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and affo...

Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 | Benzinga

2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. The forthcoming year will provide the first...
Previous 10 Next 10